Training Grant in Cancer Biology

此修订申请寻求续订11-15年的癌症生物学培训计划(T32CB) 马里兰州巴尔的摩大学格林鲍姆综合癌症中心(UMGCCC)。我们 要求每年资助4名博士后学生和4名博士后研究员。为了丰富T32CB， UMGCCC将提供一个额外的博士后职位，特别是代表人数不足的少数族裔，提高总数 T32CB博士后名额增至5个/年。T32CB专注于多学科癌症生物学研究培训 翻译任务。我们的目标是：1)在实验室和临床之间提供高效的双向翻译 通过研究和教学会议，2)在当代基础知识的关键领域提供出色的培训 和转化性癌症研究以及3)招聘和保留一支强大的专家教师导师团队，以使 学员的网络工作效率。这些目标是通过精心组织的计划实现的，该计划 确保针对癌症的特定组件的个性化灵活性。36位导师是从 UMGCCC的教职员工基于他们发表的科学成就，研究资金的记录，对 转化性癌症研究和指导学员的经验。预科部分，包括PHD 和医学/博士学者，在研究生计划的癌症生物学轨道上建立和加强培训 生命科学(GPILS)。博士后部分为博士、医学博士和医学博士/博士提供研究培训 博士后，包括外科住院医师或血液学/内科研究年中的内科科学家 肿瘤学奖学金培训。T32CB的一个长期优势是博士后学生、博士后博士后和 科学家和内科科学家并肩参加期刊俱乐部(JC)，参与正在进行的研究 (RIP)研讨会和实验室的长凳上。T32CB享有强大的机构支持和 优秀的研究培训环境，具有翻译和基础之间的协作关系 癌症研究人员和获得促进专业研究活动的尖端技术。 根据计划评估，在此续订申请中提出了几项创新，包括扩展 癌症基因组学/生物信息学和接触癌症生物工程方面的培训。专业发展 机会为所有受训人员的职业生涯下一阶段做好准备。T32CB的训练记录是非常 强项：受训人员出版成果丰硕，并获得奖项、补助金和奖学金。的有效性。 我们肩负着培养下一代癌症研究人员的使命，T32CB毕业生将100%继续 从事与研究相关的职业。T32CB利用UMGCCC对癌症差异的重视来吸引和 对代表不足的少数民族进行培训的比率很高(18%)。新的多样性咨询委员会将进一步加强 T32CB招聘和留住来自不同背景的高素质学员。我们的团队科学 在杰出导师的指导下，我们有才华的内科医生和博士科学家能够创造和贡献 有可能为癌症患者带来创新利益的跨学科科学。

This revised application seeks renewal for Years 11-15 of the Training Program in Cancer Biology (T32CB) in the Greenebaum Comprehensive Cancer Center (UMGCCC) at the University of Maryland Baltimore (UMB). We are requesting support for 4 predoctoral students and 4 postdoctoral fellows each year. To enrich the T32CB, UMGCCC will provide an additional postdoc position, especially an underrepresented minority, raising the total T32CB postdoc slots to 5/year. T32CB focuses on multidisciplinary cancer biology research training with a translational mission. Our objectives are: 1) to provide productive bidirectional translation between lab and clinic through research and didactic sessions, 2) to provide outstanding training in critical areas of contemporary basic and translational cancer research and 3) to recruit and retain a strong group of expert faculty mentors to enable networked productivity of trainees. These objectives are accomplished in a carefully structured program that ensures individual flexibility with specific cancer-focused components. The 36 mentors were selected from UMGCCC faculty based on their published scientific achievements, track record of research funding, interest in translational cancer research and experience in mentoring trainees. The predoc component, which includes PhD and MD/PhD scholars, builds from and enhances training in the Cancer Biology Track of the Graduate Program in Life Sciences (GPILS). The postdoc component provides research training for PhD, MD and MD/PhD postdocs, including physician-scientists during the research years of Surgery residency or Hematology/Medical Oncology fellowship training. A longstanding T32CB strength is integration of predoc students, postdoc PhD- scientists, and physician-scientists who participate side-by-side in journal clubs (JC), in research-in-progress (RIP) seminars and at the bench in laboratories. The T32CB enjoys strong institutional support and an outstanding research training environment, with collaborative relationships between translational and basic cancer research faculty and access to cutting-edge technologies that facilitate specialized research activities. Based on program evaluations, several innovations are proposed in this renewal application, including expanded training in cancer genomics/bioinformatics and exposure to cancer bioengineering. Professional development opportunities prepare all trainees for the next stages in their careers. The T32CB training record is extremely strong: trainees publish productively and are recipients of awards, grants and fellowships. The effectiveness of our mission to train the next generation of cancer researchers is high, with 100% of T32CB graduates continuing in research-related careers. The T32CB leverages UMGCCC’s emphasis on cancer disparities to attract and train underrepresented minorities at a high rate (18%). A new Diversity Advisory Committee will further enhance T32CB recruitment and retention of highly qualified trainees from diverse backgrounds. Our team science approach, guided by stellar mentors, enables our talented physician- and PhD-scientists to create and contribute to transdisciplinary science that is likely to yield innovative benefits for cancer patients.